Arimidex is an aromatase inhibitor and postmenopausal breast cancer treatment developed by AstraZeneca. Breast cancer cells are influenced by the female hormone estrogen when growing. When estrogen binds to the estrogen receptor, the proliferation of cancer cells is promoted, which is called hormone-sensitive breast cancer. It inhibits the development and growth of breast cancer by inhibiting the enzyme aromatase, which converts male hormones from androgens to estrogen.
Features of Arimidex
Estrogen is released by the ovaries, but after menopause it changes from the male hormone androgen to estrogen in the adrenal glands. The enzyme responsible for conversion is aromatase, which is present in mammary glands, muscles, and fat tissues. However, in the case of hormone-sensitive breast cancer, it is located within the breast cancer tissue, so estrogen is produced. Inhibiting aromatase activity inhibits the proliferation of cancer cells by reducing estrogen contained in plasma.
Effects of Arimidex
Inhibits conversion to estrogen and inhibits the growth of breast cancer.
Arimidex adaptation symptoms
Arimidex is an aromatase inhibitor, a treatment for post-menopausal breast cancer.
・ For those concerned about post-menopausal breast cancer.
Active ingredients of Arimidex
The active ingredient in Arimidex is anastrozole. It inhibits the growth of breast cancer by reducing the production of estrogen, a female hormone.
Arimidex content/content
One box contains 28 tablets. Each Arimidex tablet contains 1mg of anastrozole.
Related products
Others
